DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
2024 · Nature Communications · 76 citations
https://doi.org/10.1038/s41467-023-44237-4
S
Scott Gleim
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
43
Papers
1.4K
Citations
23
h-index
30
i10-index
Scott Gleim is an academic researcher from Novartis (United States). The author has contributed to research in topics: Receptor Mechanisms and Signaling & Inflammatory mediators and NSAID effects & Protein Degradation and Inhibitors. The author has an h-index of 23, co-authored 37 publications.
ORCID: 0000-0001-6852-0019Papers by this author
worksBiased suppression of TP homodimerization and signaling through disruption of a TM GxxxGxxxL helical interaction motif
2013 · Journal of Lipid Research · 13 citations
https://doi.org/10.1194/jlr.m036673
Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance
2024 · Nature Communications · 1 citations
https://doi.org/10.1038/s41467-024-51317-6
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat